Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survodutide DDI with Microgynon in Overweight/Obese Women
NCT05896384Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Primary completion
- Feb 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of survodutide in obesity and Overweight, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of ethinylestradiol in plasma over the time interval from 0 to the last quantifiable data point, Maximum measured concentration of ethinylestradiol in plasma and 2 more. Started Dec 2023; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05896384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896384.